Indo Farm trades margin for growth as new plants ramp up
Revenue is guided to grow 20-25% in FY27, but new capex in Bhud and tower cranes will compress EBITDA margins to 12.5%. Commercial production starts Q2.
— 3 earlier stories on Indo Farm Equipments Ltd. →What's new
- Guided for 20-25% revenue growth in FY27, but operating margins will fall to ~12.5% due to new plant ramp-ups.
- Commercial production at the Bhud expansion and for the new tower crane segment starts in Q2 FY27.
- Set a three-year target to cut working capital days from 307 to below 200 by FY29.
Why this matters
Indo Farm is spending to enter the tower crane market and expand manufacturing capacity, accepting a near-term hit to profitability. The margin compression is a deliberate trade: management is betting that new revenue streams will eventually justify the setup costs. The working-capital target is the other side of that coin—improving cash flow is critical to funding the expansion without stretching the balance sheet further.
What we're watching
- Whether the Bhud plant and crane division hit their Q2 FY27 production targets.
- If the working-capital cycle begins to shorten in the next two quarters, as targeted.
- How the 12.5% EBITDA margin holds as new segments contribute revenue.
The full read
Indo Farm is borrowing from next year's profits to fund this year's expansion. Revenue is guided to grow 20-25% in FY27, but management expects operating EBITDA margins to slip to 12.5% as it ramps up a new facility at Bhud and enters the tower crane market. Commercial production for both is set to start in Q2 FY27. The bet is that new revenue will eventually offset the setup costs. The other priority is cash: management has set a three-year target to slash working capital days from 307 to below 200 by FY29, a move aimed at improving liquidity to self-fund the growth. The margin hit is the price of the expansion. Whether the new lines deliver enough volume to justify it is the open question.
Questions answered
- Why are margins expected to decline even as revenue grows?
- The company is ramping up a new manufacturing facility at Bhud and entering the tower crane market, both of which carry significant upfront setup costs. These expenses will weigh on operating EBITDA until the new operations achieve scale.
- What is the timeline for the new tower crane business to start generating revenue?
- Commercial production for the tower crane segment is scheduled to begin in Q2 FY27, according to the earnings call. This is the first time the company will have manufacturing capability in this product line.
- How does the working-capital target relate to the expansion?
- The company plans to reduce its working capital cycle from 307 days to below 200 by FY29. Improving this metric will free up cash, which is necessary to fund the expansion without taking on excessive debt, given the current margin pressure.
- What is the base for the 20-25% revenue growth guidance?
- The guidance is for fiscal year 2027 and is driven by the new Bhud plant and the tower crane segment coming online in the second quarter. The exact FY26 base figure is not provided in the filing.
Story so far
All notes on INDOFARM →- 29 May 2026 · 6:23 PM IST Indo Farm trades margin for growth as new plants ramp up
- 3d ago Indo Farm Equipments cuts margin guidance and delays crane plant
- 9d ago Indo Farm Equipments records steady FY26 growth
- 9d ago Indo Farm Equipments records 13% consolidated revenue growth for FY26